← All trials
NCT06582966
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2024
- Primary completion
- Jun 30, 2026
- Completion date
- Jun 30, 2027
- First posted
- Sep 3, 2024
- Last posted
- Sep 3, 2024
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- University of WashingtonSponsor investigator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of WashingtonOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.